Literature DB >> 17393328

Low levels of procalcitonin during episodes of necrotizing enterocolitis.

Dan Turner1, Cathy Hammerman, Bernard Rudensky, Yechiel Schlesinger, Eytan Wine, Aleixo Muise, Michael S Schimmel.   

Abstract

The pathogenesis of necrotizing enterocolitis (NEC) remains poorly understood. We aimed to assess the extent of bacterial infection in the pathogenesis of NEC using serial procalcitonin measurements. Blood samples were drawn during the first 4 days following every clinical event requiring a workup for presumed NEC. Eight episodes were confirmed as NEC, 7 of which showed procalcitonin levels <1 ng/ml at presentation and <1.3 ng/ml thereafter, comparable to 24 healthy controls. The one infant with elevated procalcitonin had bacteremia in addition to NEC. Procalcitonin levels of 24 matched septic infants were higher than those of NEC infants, peaking at 4.1 ng/ml. We conclude that low procalcitonin values are the rule during episodes of NEC and provide further evidence that overactive local immune response, and not active infection, is primarily responsible for the mucosal damage in NEC.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17393328     DOI: 10.1007/s10620-007-9763-y

Source DB:  PubMed          Journal:  Dig Dis Sci        ISSN: 0163-2116            Impact factor:   3.199


  37 in total

1.  Acute necrotizing enterocolitis in infancy: a review of 64 cases.

Authors:  T V Sántulli; J N Schullinger; W C Heird; R D Gongaware; J Wigger; B Barlow; W A Blanc; W E Berdon
Journal:  Pediatrics       Date:  1975-03       Impact factor: 7.124

Review 2.  Enteral antibiotics for preventing necrotizing enterocolitis in low birthweight or preterm infants.

Authors:  R G Bury; D Tudehope
Journal:  Cochrane Database Syst Rev       Date:  2001

3.  The epidemiology and pathogenesis of neonatal necrotizing enterocolitis.

Authors:  David Ian Tudehope
Journal:  J Paediatr Child Health       Date:  2005-04       Impact factor: 1.954

4.  Oral probiotics prevent necrotizing enterocolitis in very low birth weight neonates.

Authors:  Alona Bin-Nun; Ruben Bromiker; Michael Wilschanski; Michael Kaplan; Bernard Rudensky; Michael Caplan; Cathy Hammerman
Journal:  J Pediatr       Date:  2005-08       Impact factor: 4.406

5.  The role of procalcitonin as a predictor of nosocomial sepsis in preterm infants.

Authors:  Dan Turner; Cathy Hammerman; Bernard Rudensky; Yechiel Schlesinger; Michael S Schimmel
Journal:  Acta Paediatr       Date:  2006-12       Impact factor: 2.299

6.  Oral probiotics reduce the incidence and severity of necrotizing enterocolitis in very low birth weight infants.

Authors:  Hung-Chih Lin; Bai-Horng Su; An-Chyi Chen; Tsung-Wen Lin; Chang-Hai Tsai; Tsu-Fuh Yeh; William Oh
Journal:  Pediatrics       Date:  2005-01       Impact factor: 7.124

Review 7.  Neonatal necrotizing enterocolitis, a disease of the immature intestinal mucosal barrier.

Authors:  E J Israel
Journal:  Acta Paediatr Suppl       Date:  1994

Review 8.  Procalcitonin as an early marker of infection in neonates and children.

Authors:  A M C van Rossum; R W Wulkan; A M Oudesluys-Murphy
Journal:  Lancet Infect Dis       Date:  2004-10       Impact factor: 25.071

9.  Early intestinal bacterial colonization and necrotizing enterocolitis in premature infants: the putative role of Clostridium.

Authors:  Marie-France de la Cochetiere; Hugues Piloquet; Clotilde des Robert; Dominique Darmaun; Jean-Paul Galmiche; Jean-Christophe Roze
Journal:  Pediatr Res       Date:  2004-06-16       Impact factor: 3.756

10.  Procalcitonin: a marker of severity of acute pyelonephritis among children.

Authors:  Paolo Pecile; Elisabetta Miorin; Carla Romanello; Edmondo Falleti; Francesca Valent; Francesco Giacomuzzi; Alfred Tenore
Journal:  Pediatrics       Date:  2004-08       Impact factor: 7.124

View more
  1 in total

1.  The efficacy of serial serum amyloid A measurements for diagnosis and follow-up of necrotizing enterocolitis in premature infants.

Authors:  Merih Cetinkaya; Hilal Ozkan; Nilgün Köksal; Okan Akaci; Taner Ozgür
Journal:  Pediatr Surg Int       Date:  2010-06-24       Impact factor: 1.827

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.